SPY334.60+0.41 0.12%
DIA275.85-0.05 -0.02%
IXIC11,127.99+10.47 0.09%

Brainstorm Announces Grant Of New Japanese Patent For NurOwn

NEW YORK, Sept. 16, 2020 /PRNewswire/ --Brainstorm Cell Therapeutics Inc.(NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese

· 09/16/2020 07:31

NEW YORK, Sept. 16, 2020 /PRNewswire/ --Brainstorm Cell Therapeutics Inc.(NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has granted Brainstorm's Japanese Patent, number: 6,753,887, titled: 'Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors'.

 

The allowed claims cover a method of generating cells which secrete neurotrophic factors from human undifferentiated mesenchymal stem cells (MSCs) derived from the bone marrow of a single donor. The said neurotrophic factors includes: brain derived neurotrophic factor (BDNF); glial derived neurotrophic factor (GDNF); hepatocyte growth factor (HGF); and vascular endothelial growth factor (VEGF).

Patent families protecting NurOwn® manufacturing have been issued in the United States, Japan, Europe, Hong-Kong and Israel.

"We are extremely pleased with the continued development of our patent portfolio protecting our technology through strategic intellectual property achievements. This new patent grant from the Japanese Patent Office is an important addition to our IP portfolio for the NurOwn® technology and is an important element of our business strategy" commented Brainstorm's CEOChaim Lebovits.

David Setboun, PharmD MBA, EVP and Chief Operating Officer, added: "Having our cell therapy product patented in Japan will increase our ability to enter into new commercial partnerships for NurOwn® in Japan."